Fasenra receives approval in Japan

Approval based on Phase III WINDWARD programme that demonstrated significantreductions in asthma exacerbations, improvements in lung function and reductions inoral corticosteroid use from baseline, versus placebo Fasenra is the first approved respiratory biologic with an 8-week maintenance dosing scheduleAstraZeneca and its global biologics research and development arm, MedImmune, today announced that the Japanese Ministry of Health, Labour and Welfare has approved Fasenra (benralizumab) as an add-on treatment for bronchial asthma in patients who continue to experience asthma